Skip to main navigation
Whitehawk Therapeutics homepage Whitehawk Therapeutics homepage Whitehawk Therapeutics homepage
Navigation
Secondary Nav
  • IR Overview
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Press Releases
  • Event Calendar
    • Upcoming Events
  • Presentations
    • Corporate Presentations
    • Scientific Presentations
  • Financial
    • SEC Filings
    • Financial Reports
    • Quarterly Results
    • Forms
  • Governance
    • Governance Highlights
    • Committee Composition
  • IR Resources
    • Investor FAQ
    • Information Request
    • Email Alerts
    • IR Contacts

Scientific Posters & Presentations

International Gynecologic Cancer Society (IGCS) Annual Global Meeting 2026
October 1, 2026
Durable and Treatment-Agnostic MUC16 Expression in Ovarian Cancer Supports Targeted Antibody-Drug Conjugate Development 6.9 MB
High MUC16 Expression Is Associated With Poor Real-World Overall Survival in Patients With High-Grade Serous Ovarian Carcinoma 317.8 KB
IASLC 2026 World Conference on Lung Cancer (WCLC)
September 14, 2026
Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development 8 MB
Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma 284.8 KB
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026
June 18, 2026
A Phase 1 Study of HWK-016, a Next-Generation, Mucin 16 (MUC16)-Directed Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors 1.6 MB
American Society of Clinical Oncology (ASCO) Annual Meeting 2026
May 30, 2026
A phase 1 study of HWK-007, a next-generation, protein tyrosine kinase 7 (PTK7)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors 1.5 MB
Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors 766.8 KB
American Association of Cancer Research (AACR) Annual Meeting 2026
April 21, 2026
Preclinical Assessment of HWK-007, a Next-Generation, PTK7-Targeting ADC with Novel Bioconjugation and Linker-Payload Technology 2.7 MB
Preclinical Assessment of HWK-206, a Next-Generation, Biparatopic, SEZ6-Targeting ADC with Novel Bioconjugation and Linker-Payload Technology 1.5 MB
American Association of Cancer Research (AACR) Annual Meeting 2026
April 19, 2026
Preclinical Assessment of HWK-016, a Next-Generation, MUC16-Targeting ADC with Novel Bioconjugation and Linker-Payload Technology 1.5 MB
Society of Gynecologic Oncology (SGO) 2026 Annual Meeting
April 12, 2026
MUC16 in ovarian cancer: high, stable expression across histologic subtypes, disease stages, and platinum sensitivity status supports antibody-drug conjugate development 3.2 MB
MUC16 as a therapeutic target: advancing antibody-drug conjugates for ovarian cancer treatment 1.6 MB
High and stable MUC16 expression in endometrial cancer highlights potential for targeted antibody-drug conjugate development 6.5 MB
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 24, 2025
Real-World Characterization of PTK7, an Oncofetal Pseudokinase Expressed in Multiple Solid Tumors 4.8 MB

Toolkit

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contacts

2 Headquarters Plaza, East Building, 11th Floor
Morristown, NJ 07960

Footer Links - Bottom
  • LinkedIn